The market is up 2.0% in the last 7 days, with all sectors gaining ground, and over the past 12 months, it has risen by 12%, with earnings forecasted to grow by 14% annually. For those looking to invest in smaller or newer companies, penny stocks—despite their somewhat outdated name—can still offer surprising value. By focusing on those with robust financials and a clear growth trajectory, investors can find opportunities that may provide both stability and potential upside.

Top 10 Penny Stocks In The United States

Click here to see the full list of 725 stocks from our US Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Real Brokerage

Simply Wall St Financial Health Rating: ★★★★★★

Overview: The Real Brokerage Inc. operates as a real estate technology company in the United States and Canada, with a market cap of approximately $849.54 million.

Operations: The company generates revenue primarily through its North American Brokerage segment, which accounts for $1.41 billion.

Market Cap: $849.54M

The Real Brokerage Inc., with a market cap of US$849.54 million, operates in the real estate technology sector and is experiencing rapid growth, evidenced by its Q1 2025 revenue of US$353.98 million. Despite being unprofitable with increasing losses over the past five years, the company has no debt and maintains a strong cash runway exceeding three years due to positive free cash flow. Recent strategic moves include a share repurchase program up to $150 million and filing for $209.5 million in shelf registration, indicating efforts to manage capital efficiently while expanding its agent network significantly across North America.

• Click here to discover the nuances of Real Brokerage with our detailed analytical financial health report.
• Review our growth performance report to gain insights into Real Brokerage's future.

Hyperfine

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Hyperfine, Inc. is a health technology company focused on the production, supply, service, and commercialization of MRI products, with a market cap of $46.90 million.

Operations: The company generates revenue from its Medical Imaging Systems segment, totaling $11.73 million.

Market Cap: $46.9M

Hyperfine, Inc., with a market cap of US$46.90 million, is navigating challenges typical of penny stocks, including high volatility and unprofitability. Despite these hurdles, the company has made significant strides with the FDA clearance of its advanced portable MRI system powered by Optive AI software. This innovation promises enhanced image quality and accessibility in diverse care settings. However, Hyperfine faces potential delisting from Nasdaq due to its stock price falling below US$1.00 for 30 days but retains options to regain compliance within specified periods. The company remains debt-free but has less than a year’s cash runway if current cash flow trends persist.

• Jump into the full analysis health report here for a deeper understanding of Hyperfine.
• Assess Hyperfine's future earnings estimates with our detailed growth reports.

Contineum Therapeutics

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for neuroscience, inflammation, and immunology in the United States, with a market cap of approximately $94.69 million.

Operations: Contineum Therapeutics, Inc. does not report any specific revenue segments.

Market Cap: $94.69M

Contineum Therapeutics, Inc., with a market cap of US$94.69 million, remains pre-revenue and unprofitable, reflecting typical challenges in the penny stock landscape. Despite these hurdles, the company has a robust cash runway exceeding three years if current free cash flow trends stabilize. Recent strategic moves include filing for $75 million in follow-on equity offerings and $300 million in shelf registrations to bolster financial flexibility. Leadership changes with Timothy Watkins as CMO aim to enhance clinical development efforts. The company's ongoing PIPE-791 trial for chronic pain treatment could yield pivotal data by early 2026, potentially impacting future growth trajectories.

• Click to explore a detailed breakdown of our findings in Contineum Therapeutics' financial health report.
• Evaluate Contineum Therapeutics' prospects by accessing our earnings growth report.

Seize The Opportunity

• Click through to start exploring the rest of the 722 US Penny Stocks now.
• Contemplating Other Strategies? Outshine the giants: these 26 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqCM:REAX NasdaqGM:HYPR and NasdaqGS:CTNM.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com